Drug profiles
Doses, kidney cutoffs, monitoring, trial evidence and every source statement for each class.
- SGLT2 inhibitorsFMT HFrEFFMT HFpEF
Dapagliflozin, Empagliflozin, Sotagliflozin (SGLT1/2 inhibitor)
- Mineralocorticoid receptor antagonists (steroidal: spironolactone, eplerenone; non-steroidal: finerenone)FMT HFrEFFMT HFpEF
Spironolactone, Eplerenone, Finerenone
- Angiotensin receptor-neprilysin inhibitor (ARNI): sacubitril/valsartanFMT HFrEFAMT HFpEF
Sacubitril/valsartan
- ACE inhibitorsFMT HFrEFAMT HFpEF
Captopril, Enalapril, Lisinopril, Ramipril, Trandolapril
- Angiotensin II receptor blockers (ARBs)FMT HFrEFAMT HFpEF
Candesartan, Losartan, Valsartan
- Evidence-based beta-blockers (bisoprolol, carvedilol, metoprolol succinate CR/XL, nebivolol)FMT HFrEF
Bisoprolol, Carvedilol, Metoprolol succinate (CR/XL), Nebivolol
- If-channel inhibitor (ivabradine)AMT HFrEF
Ivabradine
- Soluble guanylate cyclase stimulator (vericiguat)AMT HFrEF
Vericiguat
- Digoxin (renally eliminated cardiac glycoside)AMT HFrEF
Digoxin
- Digitoxin (hepatically eliminated cardiac glycoside)AMT HFrEF
Digitoxin
- Hydralazine + isosorbide dinitrate (H-ISDN)AMT HFrEF
Isosorbide dinitrate/hydralazine fixed-dose combination, Hydralazine + isosorbide dinitrate (separate tablets)
- Potassium binders (patiromer, sodium zirconium cyclosilicate)AMT HFrEFAMT HFpEF
Patiromer, Sodium zirconium cyclosilicate (SZC)
- Loop diureticsAMT HFrEFAMT HFpEF
Furosemide, Torsemide (torasemide), Bumetanide
- Thiazide and thiazide-like diuretics (sequential nephron blockade)AMT HFrEFAMT HFpEF
Hydrochlorothiazide, Metolazone, Chlorthalidone
- Carbonic anhydrase inhibitor (acetazolamide)AMT HFrEFAMT HFpEF
Acetazolamide
- GLP-1 receptor agonist / dual GIP-GLP-1 receptor agonist (semaglutide, tirzepatide) for HF with obesityAMT HFpEF
Semaglutide (subcutaneous), Tirzepatide (subcutaneous)
- Intravenous iron (ferric carboxymaltose, ferric derisomaltose)AMT HFrEF
Ferric carboxymaltose, Ferric derisomaltose